ADALVO
Adalvo, the leading global B2B pharmaceutical company, is thrilled to announce the recent establishment of a new entity ArphioTM (www.arphio.com ), a venture initiated in close collaboration with SK Pharma.
Together with our new partner, we are developing a powerhouse, solely dedicated to orphan drugs with the intention of improving accessibility of vital treatments, to patients suffering from rare diseases and unmet medical needs.
ArphioTM will operate as an independent entity, focusing on rare disease detection, market access and supply of orphan drugs, targeting the EU and ROW regions. ArphioTM has a unique understanding on orphan products and their epidemiology data and unique characteristics. The aim of this venture is to expand access to vital treatments and continue to develop technological capabilities and expertise, while maintaining a patient-centric approach with the possibility of relying on state-of-the art novel technology including worldwide data, artificial intelligence, and machine learning.
Arphio is founded by pharmaceutical professionals with expertise covering all major therapeutic areas and pharmaceutical forms in various parts of the globe. The company is focused on rare disease detection, market access and the supply of orphan drugs internationally.
Arphio is powered by DrugsIntel (DI), a data science powerhouse focusing on the aggregation, unleashing, processing, unification and deployment of pharmaceutical data covering over 75 countries, and over 6,000 sources. This intelligence tools ensure the successful launch of orphan drugs in the market of operation, based on DI’s unique methodology of these Six factors and Pillars.
This stand-alone market player will cover all services and functions ranging from medical, market access, regulatory, direct sales, and marketing activities. ArphioTM proudly boasts of strictly following ethics, compliance, accessibility, and corporate governance.
There are over 300 million people living with one or more of over 7,000 identified rare diseases around the world, each supported by family, friends, and caregivers. Currently, only about 5% of orphan disorders can be managed with an approved treatment. It is estimated that it takes about seven years and visits to 10 different doctors for a patient to receive a proper diagnostic of an orphan condition. At ArphioTM , fueled by our passion to improve people’s lives, we will apply innovative technologies to provide effective treatments for people with orphan diseases.
Anil Okay, General Manager at Adalvo comments: “We are thrilled to be partnering with SK Pharma on this exciting new journey. We welcome this opportunity to work in the domain of Orphan drugs, and we are eager to make a valuable contribution to patients across the globe who are living with Rare diseases”.
Dr. Shlomo Sadoun, CEO at SK Pharma comments: “I’m captivated to have Adalvo as our partner with the important endeavor of helping neglected orphan patients and their caregivers with their unmet medical needs. I’m bullish on the synergistical power that could outcome from this collaboration for the benefit of rare disease patients".
https://www.linkedin.com/company/arphiopr/about/
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 70 countries and for over 90 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners. With headquarters in Malta, the company has additional offices in more than 15 countries such as Switzerland, UK, Netherlands, Spain, Iceland, Austria, Romania, Hungary, Bulgaria, Portugal, Czech Republic, and India. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals. We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavors, driven by a deep-rooted passion to making a difference for partners. The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
Visit: www.adalvo.com
About SK Pharma
SK-Pharma is a global pharmaceutical company focusing on making drugs accessible to patients in needs. The vison of the company lay in utilizing cutting edge technologies to support smart business decisions that will lead to better healthcare solutions. Taking patient centric approach, the company holistically follow the patient’s journey and understand better their unmet needs. Mimicking the patient journey allow us to come with viable solutions that change the patient treatment paradigm and make it more suitable to their lifestyle and their unique needs. The group is divided to three divisions: First to launch and the introduction of complex hybrid generic products. The second division is focusing on providing technological solutions to enhance smart business decisions. The third division is specialized in orphan drugs market access and distribution worldwide. Visit: https://sk-pharma.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005409/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom